Yesterday, the Serum Institute of India announced that it will produce clinical trial doses of a new Ebola vaccine from Oxford University, backed by $8.6 million in funding from the Coalition for Epidemic Preparedness Innovations (CEPI). This initiative is part of a broader effort to combat the spreading Ebola outbreak in Africa. The vaccine uses technology similar to the Oxford-AstraZeneca Covid-19 vaccine, which has been widely used globally. The funding will support the development of the vaccine, with the goal of having trial-ready doses available soon. This investment is a significant step forward in the fight against Ebola, and Uganda, being one of the countries at risk, will likely benefit from this development. The country has been on high alert since the outbreak was reported in neighboring Democratic Republic of Congo. With this new funding, there is hope that a effective vaccine will be available soon to protect Ugandans and others in the region from this deadly disease.
On top of everything as it happens